Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.
de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, Tavan D, Petit-Laurent F, Rivoire M, Pérol D, Carrie C.
de la Fouchardière C, et al.
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):409-13. doi: 10.1016/j.ijrobp.2009.05.008. Epub 2010 Jan 29.
Int J Radiat Oncol Biol Phys. 2010.
PMID: 20116933
Clinical Trial.
METHODS AND MATERIALS: Between September 2000 and March 2008, 36 patients with histologically proven unresectable pancreas adenocarcinoma were studied prospectively. Irinotecan was administered daily, 1 to 2 h before irradiation. Doses were started at 6 mg/m(2) per day and …
METHODS AND MATERIALS: Between September 2000 and March 2008, 36 patients with histologically proven unresectable pancreas adenocarcinoma we …